| 307 |
CT Planning for SAPIEN 3 |
Euihong Ko |
Aug. 08. 19 |
| 306 |
LAA Closure: Step-by-Step from Septal Puncture to Device Detachment |
Cheung Chi Simon Lam |
Aug. 08. 19 |
| 305 |
Imaging Planning for Device Type and Size Selection |
Jung-Sun Kim |
Aug. 08. 19 |
| 304 |
Post TAVR Coronary Access with Evolut System |
Jung-Min Ahn |
Aug. 08. 19 |
| 303 |
Hands-on Teaching with Simulator |
Toru Naganuma |
Aug. 08. 19 |
| 302 |
The Next Target of the Valvular Intervention: Future Perspectives |
Eberhard Grube |
Aug. 08. 19 |
| 301 |
Optimal Antithrombotics After TAVR |
Duk-Woo Park |
Aug. 08. 19 |
| 300 |
Who Should Not Undergo TAVR? Key Insights from the Pivotal Trials and Registries |
David Joel Cohen |
Aug. 08. 19 |
| 299 |
The Optimal Antithrombotic Strategy in Patients with AF and ACS: Focusing on the AUGUSTUS Trial |
Kyung Woo Park |
Aug. 08. 19 |
| 298 |
Clinical Challenges in CKD Patients with AF: Renal Safety of Rivaroxaban |
Hong Euy Lim |
Aug. 08. 19 |
